
    
      Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study.
      The effecy and safety of the four PD-1 agents according to clinical outcomes in real world
      will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab,
      toripalimab, sintilimab）
    
  